Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

Phase 3

• Conditions: Diabetic Retinopathy
• Interventions: Drug: bevacizumab

• Registration Number: NCT00370721
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03
• Study First Submitted: 2006-08-30
• Study First Submitted QC: 2006-08-30
• Study First Posted: 2006-09-01
• Status Verified: 2008-06
• Last Update Submitted: 2008-06-25
• Last Update Posted: 2008-06-26

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Cases of active progressive PDR with history of scatter laser photocoagulation

Exclusion Criteria

• history of vitrectomy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
I	bevacizumab	-

Primary Outcome Measures

Name	Time	Method
Regression of diabetic retinopathy
visual acuity

Secondary Outcome Measures

Name	Time	Method
neovascularization
fibrous proliferation
traction retinal detachment
vitreous hemorrhage
pan retinal photocoagulation

Trial Locations

Locations (1)

Hamid Ahmadieh, MD; 🇮🇷 Tehran, Iran, Islamic Republic of